Trials / Completed
CompletedNCT00192335
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 890 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 5 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
* Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist * Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAIV-T | |
| BIOLOGICAL | CAIVT | The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril). |
| BIOLOGICAL | FluMist | The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). |
Timeline
- Start date
- 2004-07-01
- Completion
- 2005-02-01
- First posted
- 2005-09-19
- Last updated
- 2007-11-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00192335. Inclusion in this directory is not an endorsement.